Pancreatic acinar cell carcinoma with bilateral ovarian metastases, panniculitis and polyarthritis treated with FOLFIRINOX chemotherapy regimen. A case report and review of the literature

Callata-Carhuapoma, Héctor Randhall; Cour, E. Pato; González-Astorga, Beatriz; Fernandez, Ramiro Mendez; Fernandez, Maria Luisa Mendoza; Manzano, Aránzazu; Rosa, C. Aguado de la; Sotelo, Miguel; Cabezas-Camarero, Santiago; Varela, Javier Sastre

doi:10.1016/j.pan.2015.04.006

Cited by 19 publications

(10 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…As many of these patients present with late‐stage disease, thereby precluding them from surgical resection, much of their care is directed toward symptom relief and palliation. Successful chemotherapy regimens mentioned have used FOLFIRINOX . Successful elimination of liver metastases with chemoembolization using a regimen of mitomycin, DSM450, cisplatin, and Lipiodol has also been noted to have drastic improvement in LHS symptoms .…”

Section: Discussionmentioning

confidence: 99%

Lipase hypersecretion syndrome: A rare cutaneous manifestation of advanced pancreatic acinar cell carcinoma

Nizam

Shah

Rajack

et al. 2020

Clinical Case Reports

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Lipase hypersecretion syndrome: A rare cutaneous manifestation of advanced pancreatic acinar cell carcinoma

Nizam

Shah

Rajack

et al. 2020

Clinical Case Reports

View full text Add to dashboard Cite

show abstract

“…Considering the promising data for FOLFIRINOX against advanced pancreatic cancer (18), the present patient was treated with this regimen. Combination chemotherapy employing oxaliplatin or irinotecan for the treatment of colorectal cancer may be effective in PACC, as these tumors are associated with abnormalities in the APC/β-catenin pathway, similar to colorectal carcinomas, and FOLFOX therapy has also been administered to PACC patients (19).…”

Section: Discussionmentioning

confidence: 99%

Pancreatic acinar cell carcinoma presenting with panniculitis, successfully treated with FOLFIRINOX: A case report

Yoshihiro

Nio

Tsuchihashi

et al. 2017

Molecular and Clinical Oncology

View full text Add to dashboard Cite

Pancreatic acinar cell carcinoma (PACC) is a rare tumor of the exocrine pancreas, representing only 1% of all pancreatic malignancies. A 50-year-old man presented with edema of the thumb joints bilaterally, followed by an appearance of masses in the bilateral lower extremities and fever (38°C). The masses were diagnosed as panniculitis by skin biopsy, and multiple intraperitoneal masses were incidentally detected on pelvic magnetic resonance imaging performed to investigate the leg abnormalities. The patient was referred to the Kyushu University Hospital for further investigation, and fluorodeoxyglucose-positron emission tomography/computed tomography (CT) revealed high-uptake tumors in the pancreatic tail, in the periphery of the liver, and in the pelvis. Laboratory examinations revealed high serum concentrations of pancreatic exocrine enzymes, such as lipase, trypsin, elastase 1 and pancreatic phospholipase A2. Histological examination of a bioptic specimen obtained from a hepatic lesion revealed proliferation of atypical cells arranged in a tubular or glandular pattern. Immunohistochemical staining revealed that the atypical cells were positive for cytokeratin (CK)7, CK19 and lipase, but negative for CK20 and thyroid transcription factor-1, leading to a final diagnosis of acinar cell carcinoma of the pancreatic tail (T4bN0M1, stage IV according to the 7th edition of the TNM Classification of Malignant Tumors). Combined chemotherapy with oxaliplatin, irinotecan and fluorouracil (FOLFIRINOX) was administered and fever was soon alleviated. The serum levels of lipase also declined and panniculitis completely resolved. As of the start of the 8th course of chemotherapy, the levels of the pancreatic exocrine enzymes were within normal ranges and CT revealed partial response. Therefore, the severe lipase hypersecretion syndrome was well controlled by the FOLFIRINOX regimen and shrinkage of the mass was also achieved. Thus, the FOLFIRINOX regimen may represent an effective treatment option for advanced PACC.

show abstract

“…FOLFIRINOX has been used as a standard regimen of neoadjuvant therapy for pancreatic ductal adenocarcinoma, but it has also been reported to be effective for unresectable ACC in a few papers. 4 Use of FOLFIRINOX for the patients with MAEC or ACC may be appropriately considered as a choice of downstaging therapy for patients with borderline resectable or locally advanced disease.…”

Section: Discussionmentioning

confidence: 99%

Preoperative Treatment With FOLFIRINOX and Successful Resection for a Patient With Mixed Acinar-Endocrine Carcinoma of the Pancreas

et al. 2017

View full text Add to dashboard Cite

Pancreatic acinar cell carcinoma with bilateral ovarian metastases, panniculitis and polyarthritis treated with FOLFIRINOX chemotherapy regimen. A case report and review of the literature

Cited by 19 publications

References 33 publications

Lipase hypersecretion syndrome: A rare cutaneous manifestation of advanced pancreatic acinar cell carcinoma

Lipase hypersecretion syndrome: A rare cutaneous manifestation of advanced pancreatic acinar cell carcinoma

Pancreatic acinar cell carcinoma presenting with panniculitis, successfully treated with FOLFIRINOX: A case report

Preoperative Treatment With FOLFIRINOX and Successful Resection for a Patient With Mixed Acinar-Endocrine Carcinoma of the Pancreas

Contact Info

Product

Resources

About